Stephens & Co. Maintains Equal-Weight on Anika Therapeutics, Lowers Price Target to $23
Portfolio Pulse from jenniferd'souza@benzinga.com
Stephens & Co. analyst George Sellers has maintained an Equal-Weight rating on Anika Therapeutics (NASDAQ:ANIK) but lowered the price target from $28 to $23.
August 10, 2023 | 2:16 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Anika Therapeutics' price target has been lowered from $28 to $23 by Stephens & Co., though the Equal-Weight rating is maintained.
The lowering of the price target by Stephens & Co. indicates a less optimistic outlook for Anika Therapeutics, which could negatively impact the stock's price in the short term. However, the maintenance of the Equal-Weight rating suggests that the company's overall performance is expected to be in line with the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100